Vaxart Inc (VXRT)

$VXRT As another example.. Source: Reuters https://search.app/HQTVX

$VXRT @Vaxylove VXRT also has potential in cancer pill pipeline.

$VXRT We will get through all the struggles and obstacles by kicking out VXRT board and nominating our own VXRT board members. VXRT market maker also must be kicked out. Partnerships are homeruns for VXRT. We need concenerd VXRT investor group to get to the finish line.

$VXRT Blow The Doors Off The tweet below is from February 2024, nearly two years ago. Our original construct was durable and cross-reactive to all tested CoV-2 variants. And now we have a next gen that is 40 - 100x more immunogenic. The 400-subject data could blow the door off of this play, even if the masses don't believe Covid is a thing anymore. If data is positive, it could: 1. Unlock global funding. 2. Open new partnerships (pharma, government, global health orgs) for additional indications. 3. Improve investor sentiment, leading to better access to capital, higher valuations, and ability to fund other programs. 4. Accelerate regulatory discussions with the FDA, and/or seeking conditional approvals/fast track if the data are compelling. 5. Give us platform credibility and real-world validation, which helps with licensing and global distribution deals, especially in LMIC's where cold-chain is a barrier. I disagree with those who say we'll be lucky to get to $3 - $5 in a few years. The way I see it, we don't have to wait to go to market to make some serious coin. Once we land one major partnership, perception will change and the dominos will start falling: Additional funding, partnerships, licensing deals, global attention. Imagine multiple governments signing on for Noro. And Gates buying hundreds of millions of doses for Gavi. And this cycle will continue. The best part is we won't have to push it. Every year, institutions and governments will simply reorder.

$VXRT @ndouglas48 thoughts on the close this week?

$VXRT HARPUA.........NO ON RS FOREVER!!! VERY HAPPY WITH MY CHOICE TO VOTE NO AND WILL CONTINUE TO DO SO.

$VXRT Posted on LinkedIn

$VXRT @AnilDK79 If Covid vaccine is approved and gets to market, I’d estimate market cap rising to between $1B - $3B, with the higher end being if it looks like Noro is headed in the right direction too. But again, that is likely 3-5 years out. Here’s why: - It will be another 12 months until we have results from this P2B trial. - Next is a P3, which from design to enrollment to completion will likely be another 18 months. - Then it’s 1-3 months of statistical analysis by Vaxart. - Then it’s ~2 months for FDA to review a BLA - After that, the FDA review clock starts. If designated as priority, that’s ~6 months. Otherwise closer to 10 months. - Finally, the vaccine advisory committee meets to review, which could add up to another 1-2 months. - And then, if all goes well, we get approval and can begin manufacturing and distribution. So when you add it up, it’s 40-48 months from now when we would likely go to market, and that’s if there are no hiccups or delays. If no dilution happens between now and then (not likely, but we can hope), a $1B- $3B valuation would mean a share price of $4.50 - $13. I’ve never said it’s impossible to get there, just that guys like @SackLo need to get real about how long it’s going to take and that no matter who is at the helm, he’s not going to see 10x share price by end of Q1.

$VXRT @MaxToMax22 Sure I can! Look, I’m doing it right now! Shareholders made a big mistake rejecting the r/s. But what’s done is done. And again, the no voters won fair and square, and I accept the defeat. The topic only came up because folks here continue to talk about achieving insane share prices in the near-term, and that is highly unlikely from OTC. This message board spent a lot of time talking about “save our shares,” etc, but not much time considering the downside of OTC. It’s going to be a wake up call for a lot of people when they see that a partnership doesn’t suddenly 10x the share price. Could’ve happened from Nasdaq because of institutional buyers and retail FOMO, but neither of those work from OTC. I still believe we can see material share price growth, just going to take years to happen from OTC.